NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»09/09/2009 [Industry news]
China Biologic Products Appoints Director of Research and Development

The company announced that it has appointed Dr. Vincent Yi-Wu Xie to be the Company\'s Director of Research and Development, effective September 1, 2009, to oversee the development of new biologic products covering processes, analytical methods and indications.

 
China Biologic Products, Inc., one of the leading plasma-based pharmaceutical companies in China, operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Chongqing Dalin Biologic Technologies Co., Ltd and its equity investment in Xi\'an Huitian Blood Products Co., Ltd., today announced that the Company has appointed Dr. Vincent Yi-Wu Xie to be the Company\'s Director of Research and Development, effective September 1, 2009, to oversee the development of new biologic products covering processes, analytical methods and indications. Dr. Xie is a veteran in the biopharmaceutical industry and has published several papers and articles related to the field of plasma-based research. He holds a number of patents related to his biopharmaceutical research, including research on plasma-derived hyperimmune globulins and alpha-1 proteinase inhibitor, and has received the Guangzhou City Science and Technology Award in connection with his work \"Preparation of Equine Antibodies against Avian Influenza.\" Prior to joining China Biologic, Dr. Xie served from 2007 to 2009 as the General Manager of Research and Development at New a-IKOR Limited, a Hong Kong-based biopharmaceutical company, and from 2002 to 2007, as the Director of Research & Development at Advantek Serum Laboratories Limited, a Hong Kong plasma-based biopharmaceutical company. Dr. Xie has also conducted postdoctoral research in various departments in the University of Hong Kong and the Chinese University of Hong Kong. \"We are very pleased to have Dr. Xie join our research team,\" commented Mr. Chao Ming Zhao, CEO of China Biologic Products. \"He brings years of research experience and managerial expertise related to the biopharmaceutical industry to China Biologic Products. We expect that his presence on our team will serve to strengthen our research and development efforts as part of our strategy to bring new higher margin products to market.\"

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.